Cargando…
Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization
Some studies have shown that sorafenib could significantly prolong the overall survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE). However, other studies revealed that patients had no access to sorafenib-related survival benef...
Autores principales: | He, Kun, Yang, Zelong, Liu, Xinyu, Yang, Yanling, Song, Wenjie, Wang, Shangyu, Chen, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857819/ https://www.ncbi.nlm.nih.gov/pubmed/36661687 http://dx.doi.org/10.3390/curroncol30010038 |
Ejemplares similares
-
Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma
por: NISHIKAWA, HIROKI, et al.
Publicado: (2012) -
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016) -
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib
por: Fu, Sirui, et al.
Publicado: (2016) -
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis
por: Cai, Rong, et al.
Publicado: (2017) -
Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma
por: Lee, Wei‐Chen, et al.
Publicado: (2020)